Form 4: Doximity Director Wampler Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Kira Scherer Wampler, a director at Doximity, Inc., executed stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On March 3, 2025, Kira Scherer Wampler, a director of Doximity, Inc., exercised stock options to acquire 2,000 shares of Class A Common Stock.
- Simultaneously, Wampler sold 2,000 shares of Class A Common Stock at a price of $70.89 per share.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2024.
- Following these transactions, Wampler directly owns 16,618 shares of Class A Common Stock and 485,700 shares of Class B Common Stock.
- Wampler also holds options to purchase 2,000 shares of Class B Common Stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing trading plan. There is no indication of positive or negative implications for the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the trading activities of company directors. The use of a 10b5-1 trading plan is a common practice to allow insiders to sell shares without concerns about potential insider trading violations.
Comparison to Industry Standards
- Comparing Doximity's insider trading activity to companies like Teladoc Health or Veeva Systems would provide context.
- Examining the frequency and volume of insider sales in relation to market capitalization and stock performance would be useful.
- Analyzing the adoption and execution of 10b5-1 plans across the healthcare technology sector can offer insights into Doximity's practices.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares by a director.
- The impact is likely minimal as the transactions were pre-planned and represent a small portion of the director's holdings.
Key Dates
| Date | Description |
|---|---|
| March 27, 2020 | Start date for the 36-month vesting schedule of the stock option. |
| June 10, 2020 | Date the stock option was granted. |
| November 12, 2024 | Date the Rule 10b5-1 trading plan was adopted. |
| March 3, 2025 | Date of the reported transactions (option exercise and stock sale). |
| March 5, 2025 | Date of the Form 4 filing. |
| June 9, 2030 | Expiration date of the stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.